Good evening :)
Place Order
Add to Watchlist

Natco Pharma Ltd

NATCOPHARM

Natco Pharma Ltd

NATCOPHARM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹24,636 cr, stock is ranked 304
Moderate RiskStock is 2.38x as volatile as Nifty
1,429.651.03% (+14.55)
1,429.651.03% (+14.55)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹24,636 cr, stock is ranked 304
Moderate RiskStock is 2.38x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹24,636 cr, stock is ranked 304
Moderate RiskStock is 2.38x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
12.674.210.69%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.116.510.52%

Forecast & Ratings

Detailed Forecast 
56%
Analysts have suggested that investors can buy this stock

from 9 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).

Investor Presentation

View older 

Nov 12, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.15%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.01% to 1.09%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 16.59%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,054.102,034.102,225.202,224.702,022.402,155.702,043.802,811.704,126.904,751.50
Raw Materialssubtract318.90617.90436.40388.10456.80559.50577.70651.00673.902,186.10
Power & Fuel Costsubtract43.7050.5056.2059.6062.4061.1076.4081.9088.90
Employee Costsubtract179.80243.20325.60355.90375.00414.90444.80486.70525.00
Selling & Administrative Expensessubtract180.90299.60304.50351.10311.60300.90367.70388.80604.00
Operating & Other expensessubtract53.40125.60133.70145.00126.60109.50214.70163.10355.60
Depreciation/Amortizationsubtract50.8054.4066.2081.0099.80116.90142.60163.80186.80189.60
Interest & Other Itemssubtract22.9018.5015.4019.3021.5013.3017.7014.5019.2020.10
Taxes & Other Itemssubtract46.60138.40191.00180.30107.90138.7032.20146.60285.20410.90
EPS9.2327.8938.8135.0925.2624.209.3239.2276.79108.58
DPS1.256.758.256.256.755.254.505.509.505.50
Payout ratio0.140.240.210.180.270.220.480.140.120.05

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 7PDF
Feb 17PDF
Nov 15PDF
Aug 18PDF
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
Feb 9PDF
Nov 11PDF
Aug 10PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 12PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Natco Pharma Ltd17.754.210.69%
Sun Pharmaceutical Industries Ltd44.626.370.76%
Cipla Ltd30.064.620.85%
Torrent Pharmaceuticals Ltd67.9216.410.84%

Price Comparison

Compare NATCOPHARM with any stock or ETF
Compare NATCOPHARM with any stock or ETF
NATCOPHARM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.15%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding49.62%2.37%4.39%17.51%26.12%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep11.02%12.82%13.72%16.14%17.45%17.51%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Natco Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
TATA MUTUAL FUND EQ P/E DIRECT GROWTH OPEN ENDED

Growth
0.8899%2.62%0.39%14/55 (+3)
Tata Small Cap Fund-Direct Plan-Growth

Growth
0.3986%1.04%-0.41%38/58 (-11)
Canara Robeco Emerging Equities - Growth - Direct Plan

Growth
0.2509%0.26%-0.02%89/96 (-9)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.69%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.91 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateNov 27, 2024

Interim 2
Interim 2 | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Nov 27, 2024

Cash Dividend

Ex DateEx DateAug 23, 2024

Interim
Interim | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Aug 23, 2024

Cash Dividend

Ex DateEx DateFeb 26, 2024

Interim 3
Interim 3 | Div/Share: ₹1.25

Dividend/Share

₹1.25

Ex DateEx Date

Feb 26, 2024

Cash Dividend

Ex DateEx DateNov 24, 2023

Interim 2
Interim 2 | Div/Share: ₹1.25

Dividend/Share

₹1.25

Ex DateEx Date

Nov 24, 2023

Cash Dividend

Ex DateEx DateAug 22, 2023

Interim
Interim | Div/Share: ₹7.00

Dividend/Share

₹7.00

Ex DateEx Date

Aug 22, 2023

News & Opinions
Spotlight
Natco Pharma Ltd soars 1.05%, Gains for third straight session

Natco Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1429.95, up 1.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Natco Pharma Ltd has added around 1.49% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 7.85 lakh shares today, compared to the daily average of 7.49 lakh shares in last one month.The PE of the stock is 13.78 based on TTM earnings ending September 24.Powered by Capital Market - Live

4 hours agoCapital Market - Live
Spotlight
Natco Pharma sells Telangana land for Rs 116 crore

The drug maker stated that since no business operations are carried out on the said land and building being sold, the sale will not have any impact on the business operations of the company. Further, the sale of the said property does not constitute an undertaking or substantially the whole of the undertaking for the company in terms of Section 180(1)(a) of the Companies Act, 2013. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India, which cater to both domestic and international markets, including regulated markets like the United States of America and Europe. The company's consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.11% to currently trade at Rs 1,362.65 on the BSE.Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Natco Pharma submits ANDA with USFDA for Risdiplam for Oral solution

Natco Pharma today announced submission of Abbreviated New Drug Application (ANDA) with USFDA  for Risdiplam for Oral Solution. NATCO believes it is amongst one of the first two companies to have filed a substantially-complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. NATCO has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. EVRYSDI' has recorded sales of USD 571 million in the US market for the year 2023. Risdiplam for Oral Solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Natco Pharma submits ANDA with US FDA for Risdiplam

The ANDA is a generic version of Evrysdi (Risdiplam) for oral solution by Genentech Inc. Risdiplam for oral solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. The drug maker believes it is amongst the first two companies to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. The company has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. Evrysdi has recorded sales of $571 million in the US market for the year 2023. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like the United States of America and Europe. The company's consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.64% to currently trade at Rs 1,374.95 on the BSE.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Natco Pharma fixes record date for interim dividend

Natco Pharma has fixed 27 November 2024 as record date for taking on record of its shareholders eligible for the purpose of payment of second interim dividend. The dividend will be paid from 04 December 2024. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Natco Pharma Ltd eases for fifth straight session

Natco Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1376.75, down 1.01% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Natco Pharma Ltd has eased around 3.09% in last one month.Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 15.6 lakh shares today, compared to the daily average of 4.86 lakh shares in last one month.The PE of the stock is 16.23 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Natco Pharma consolidated net profit rises 83.55% in the September 2024 quarter

Net profit of Natco Pharma rose 83.55% to Rs 677.30 crore in the quarter ended September 2024 as against Rs 369.00 crore during the previous quarter ended September 2023. Sales rose 32.94% to Rs 1371.10 crore in the quarter ended September 2024 as against Rs 1031.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1371.101031.40 33 OPM %58.6644.41 - PBDT864.00483.20 79 PBT818.20439.60 86 NP677.30369.00 84 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Board of Natco Pharma recommends second interim dividend

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 November 2024, inter alia, have recommended the second interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Natco Pharma gains as Q2 PAT jumps 84% YoY to Rs 677 cr

Revenue from operations was at Rs 1,371.1 crore in Q2 FY25, up 32.93% from Rs 1,031.4 crore posted in Q2 FY24. The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharma business. Total income jumped 35.26% year on year to Rs 1,434.9 crore in the quarter ended 30 September 2024. Profit before tax in Q2 FY25 stood at Rs 818.20 crore, up 86.12% as against Rs 439.60 crore reported in the same period a year ago. The company's revenue from API stood at Rs 49.6 crore (down 36.24% YoY), income from domestic formulations was at Rs 102.3 crore (down 0.19% YoY) and revenue from crop health sciences (CHS) came in at Rs 14.1 crore (down 74.73% YoY) during the period under review. On the other hand, revenue from exports formulations jumped 52.88% YoY to Rs 1,211.3 crore during the quarter. Meanwhile, the company's board declared a second interim dividend of Rs 1.50 per equity share in FY25. The record date for the same is fixed on Monday, 25 November 2024. The payment of the dividend will start from 2 December 2024. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Natco Pharma fixes record date for 2nd interim dividend

Natco Pharma has fixed 25 November 2024 as record date for 2nd interim dividend of Rs 1.50 per share for FY 2024-25. The dividend will be paid on 02 December 2024. Powered by Capital Market - Live

3 weeks agoCapital Market - Live